Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRYSTAL-1: MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation
NCT03785249Phase 2Active, not recruiting
- Sponsor
- Mirati Therapeutics
- Start
- Jan 2019
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2 trial of adagrasib in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 1 more (9 arms), sponsored by Mirati Therapeutics. Primary endpoints: Safety and tolerability of MRTX849 at 20 months, Pharmacokinetics of MRTX849 at 20 months and 1 more. Started Jan 2019; status: active, not recruiting.
02
Drugs
adagrasib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03785249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785249.